Key Segments:
By Technology
-
Radiofrequency Renal Denervation Systems
-
Ultrasound Renal Denervation Systems
-
Chemical Renal Denervation Systems
-
Others
By Product Type
-
Catheters
-
Generators/Energy Consoles
-
Accessories
-
Disposable Components
By Application
-
Resistant Hypertension
-
Uncontrolled Hypertension
-
Chronic Kidney Disease with Hypertension
-
Clinical Research
By End User
-
Hospitals
-
Cardiac Catheterization Laboratories
-
Ambulatory Surgical Centers
-
Specialty Cardiovascular Clinics
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company's specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Technology X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key Palyers include Medtronic plc, ReCor Medical, Inc. (Otsuka Holdings Co., Ltd.), Boston Scientific Corporation, Johnson & Johnson MedTech, and Abbott Laboratories, among others.
The major growth factor is rising resistant hypertension prevalence, expanding regulatory approvals, and growing clinical evidence supporting durable blood pressure reduction from catheter-based ablation.
The Radiofrequency Renal Denervation Systems segment dominated the Renal Denervation Devices Market by technology, representing the largest share of revenue in 2025.
North America dominated the Renal Denervation Devices Market in 2025, holding an estimated 52.60% share of total global market revenue.